Today: 19 July 2026
Browse Category

NYSE:KMB 22 October 2025 - 19 December 2025

Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue Inc.—the consumer health company behind brands such as Tylenol, Band-Aid, Listerine, Neutrogena, and Aveeno—is trading in a market that feels less like “buy-and-hold fundamentals” and more like “event-driven probability.” The reason: Kimberly-Clark’s planned acquisition of Kenvue, a deal that has put a very visible “price anchor” on KVUE… while lawsuits, regulatory steps, and the calendar to closing keep the stock from simply snapping to the offer value. investors.kenvue.com+2Reuters+2
15 December 2025
Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

KVUE Stock Today (Nov. 18, 2025): Shares Slip as Appeals Court Weighs Tylenol Cases; Dividend Cleared; Kimberly‑Clark Deal Spread Persists

KVUE softened today after Monday’s developments in federal litigation tied to claims that prenatal acetaminophen use raises autism risk. A three‑judge appeals panel questioned the lower court’s dismissal of those cases, opening the door to their potential return and keeping headline risk front‑and‑center for the stock. Reuters
P&G Earnings Smash Estimates – Beauty Boom and Razors Fly Off Shelves in Q1

PG Stock Today: What to Know Before the Bell on November 10, 2025 (Earnings, Dividend, Tariffs, and Sector M&A)

Summary• PG closed Friday, November 7 at $146.98, sitting near the low end of its 52‑week range. Market cap is about $343B. StockAnalysis+1• P&G’s latest quarter delivered net sales of $22.4B, organic sales +2%, and core EPS of $1.99. FY26 guidance: all‑in sales +1% to +5%, core EPS $6.83–$7.09; management now bakes in ~$400M after‑tax tariff headwind and ~$100M commodity headwind, offset by an FX tailwind of ~$300M. PG Investor• Dividend watch: the next $1.0568 per‑share payout lands Monday, November 17. Trailing forward yield is ~2.9% at current prices. PG Investor+1• Leadership transition: COO Shailesh Jejurikar becomes CEO on Jan. 1, 2026; Jon Moeller shifts to executive chairman—operational continuity is expected but investors will listen for transition color. us.pg.com• Legal overhang to watch: a federal judge just allowed a lawsuit over Kid’s Crest packaging to proceed. While damages, if any, are unclear, headlines can sway sentiment in the near term. Reuters• Sector backdrop: Kimberly‑Clark’s bid to buy Kenvue for >$40B reshapes staples, with implications for categories where P&G competes. Reuters+1• Macro this week: October CPI hits Thursday, Nov. 13. Into Monday, the 10‑year Treasury last printed ~4.11% and DXY hovered near 99.6—levels that often influence defensives’ multiples. Bureau of Labor
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue Inc. is a leading consumer health company formed from Johnson & Johnson’s storied consumer products division. The name “Kenvue” combines “ken” and “vue”, reflecting a vision of insight-driven careen.wikipedia.org. As a spin-off, Kenvue took over J&J’s well-known retail brands, ranging from over-the-counter medicines to skincare and baby care. Today its portfolio spans three segmentsinvesting.com:
Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kenvue’s stock soared on the buyout news, delivering a sharp one-day gain. As of midday Nov. 3, KVUE traded around $17–$18, up roughly 18–20% intraday Reuters. Prior to the announcement, the stock had closed at $14.37 on Oct. 31 Stockanalysis, near its 52-week low of ~$14.02 Reuters Reuters. The takeover premium immediately boosted KVUE, though the share price remained a bit below the offer value – typical in cash/stock mergers as arbitragers factor in execution timing and Kimberly-Clark’s own stock movement Reuters. Overall, the market reaction reflected optimism for Kenvue shareholders locking in a significant premium after a prolonged slump. By contrast, Kimberly-Clark’s stock declined on fears of deal dilution and debt load, since KMB will partly fund the cash portion via new debt and a business unit sale Prnewswire.
Investors Beware: 7 Stocks to Avoid on October 22, 2025 Amid Alarming Warnings

Investors Beware: 7 Stocks to Avoid on October 22, 2025 Amid Alarming Warnings

Even market darlings are showing cracks. Netflix shocked Wall Street this week with an earnings miss – a rarity for the streaming leader. An unexpected Brazilian tax dispute dragged down Netflix’s Q3 profit, causing its shares to tumble 6–7% in pre-market tradingreuters.com. The company slightly raised its year-end forecast, but that wasn’t enough to calm investorsreuters.com. The stumble highlights how high expectations leave zero margin for error in richly valued tech names. Analysts note that with stocks priced “for perfection,” any surprise expense or growth slowdown can send them reelingts2.tech. Netflix’s slip has put the entire streaming sector on notice, reminding investors that intense competition and rising costs can quickly undercut growth narratives.
Go toTop